Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03619083 : Assessment of Sensory Gating, Attention, and Executive Control in Breast Cancer
Phase
AgesMin: 40 Years Max: 75 Years
Eligibility
Inclusion Criteria:

For Patients:

- Female

- Age 40-75 at diagnosis of a new primary histological confirmed adenocarcinoma breast
cancer

- AJCC stages 0-3 breast cancer

- Post-surgery for current breast cancer diagnosis Score of < 11 on the Blessed
Orientation-Memory-Concentration Test (BOMC)

- If currently taking psychoactive medications (including but not limited to
antidepressants and anxiolytics), dose must have been stable at least two months prior
to enrollment.

- English fluent (as per self reported fluency of "very well")**

For Healthy Controls:

- Female

- Age 40-75

- If currently taking psychoactive medications (including but not limited to
antidepressants and anxiolytics), dose must have been stable at least two months prior
to enrollment.

- As per self report, no history of cancer except non-melanoma/basal cell skin
cancer/squamous cell skin carcinoma

- Score of < 11 on the Blessed Orientation-Memory-Concentration Test (BOMC)

- English fluent (as per self reported fluency of "very well")**

Exclusion Criteria:

For All Participants:

- Diagnosis of neurodegenerative disorder that affects cognitive function (e.g.
Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Dementia, Seizure
Disorders, etc.)

- As per medical record or self report, history of stroke or head injury requiring visit
to the emergency room or hospitalization

- As per medical record or self report, a diagnosis of a Schizophrenia Spectrum
Disorder, substance use disorder, Bipolar Disorder or Schizotypal personality
disorder. Schizophrenia Spectrum Disorders include Schizophrenia, Schizophreniform
disorder, Schizoaffective disorder, Delusional disorder, Brief psychotic disorder, and
Attenuated Psychotic Disorder.

- Visual or auditory impairment that would preclude ability to complete the assessments
(e.g. history of significant macular degeneration or being unable to correct hearing
with hearing aides)

- Use of methotrexate (Amethopterin, Rhematrex, Trexall) or rituximab (Rituxin) for
rheumatoid arthritis, psoriasis or Crohn's disease, or cyclophosphamide (Cytoxan,
Neosar) for Lupus.

For Patients only:

- History of another type of cancer or prior breast cancer diagnosis except
non-melanoma/basal cell skin cancer/squamous cell skin carcinoma

- Disease recurrence as per medical record. ** Language verification: For both patients
and controls, prior to enrollment, all will be asked the following two questions by an
RSA to verify English fluency necessary for participation in the study:

1. How well do you speak English? (must respond "Very well" when given the choices
of Very well, Well, Not well, Not at all, Don't know, or Refused)

2. What is your preferred language for healthcare? (must respond English)
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03619083      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740